A Mutation-Based Reverse Vaccinology Approach Considering Variability in Epitopes to Combat Multi-Strains: A Study Using Glycoprotein of LASV
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a novel Lassa virus (LASV) vaccine using mutation-based reverse vaccinology. The epitope-based vaccine targets LASV strain variability, showing promising results in silico for effective immune response and broad coverage.
Area Of Science
- Virology
- Immunology
- Vaccine Development
- Bioinformatics
Background
- Lassa virus (LASV) poses a significant public health threat due to its strain variability, limiting current therapeutic effectiveness.
- Developing a vaccine that addresses LASV's genetic diversity is crucial for effective disease control.
Purpose Of The Study
- To design and evaluate a mutation-based, epitope-derived vaccine against Lassa virus (LASV) by incorporating variable regions of the glycoprotein.
- To assess the immunogenicity, structural integrity, and binding affinity of the proposed vaccine candidates.
Main Methods
- Reverse vaccinology approach to identify B-cell (LBL) and T-cell (MHC-I, MHC-II) epitopes from LASV glycoprotein.
- In silico construction of wild and mutated epitope-based vaccines with an adjuvant (PADRE) and 6xHis-Tag.
- Computational analysis including 3D structure prediction, molecular docking with TLR-2, molecular dynamics simulation, immune simulation, and in silico cloning in E. coli.
Main Results
- Identified 2 LBL, 21 MHC-I, and 8 MHC-II epitopes, with wild and mutated variants constructed.
- Vaccine constructs exhibited favorable 3D structure quality (91.5% wild, 91% mutated) and high population coverage (94%).
- Strong binding affinity to TLR-2 (-11.1 kcal/mol wild, -19.9 kcal/mol mutated), stable molecular dynamics, robust immune response, and efficient expression in E. coli.
Conclusions
- The integrated in silico approach successfully designed mutation-based epitope vaccines against LASV.
- The developed vaccine candidates demonstrate potential for broad protection against diverse LASV strains.
- This strategy offers a promising platform for developing next-generation vaccines against variable viruses.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Overview
The ability of a single antibody to recognize multiple structurally similar epitopes is an important immune defense strategy that enables the host to efficiently defend against many potentially threatening pathogens. However, cross-reactivity also elicits allergy symptoms against related allergens. It is increasingly important to understand the principles of cross-reactivity, as antibodies are actively being developed as therapeutic modalities for diverse diseases, including cancer.
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
Viral Recombination Can Create New Diseases
Some diseases can infect multiple species. For example, pigs can be infected by some human and...